Adverse events associated with anti-VEGF therapy are mainly injection-related and include cataracts, vitreous haemorrhage, uveitis and ocular inflammation, floaters, retinal vessel changes, retinal detachment, endophthalmitis and elevated intraocular pressure [38, 84]. This evidence concerns the gene VEGFA and cataract.